Botulinum toxin in the treatment of post-traumatic headache - case study;Toksyna botulinowa w leczeniu pourazowego bólu głwy - opis przypadku

Neurologia i Neurochirurgia Polska

Volumn 46, Issue 6, 2012, Pages 591-594

  Lippert Grüner, Marcela ^a,b,c  

^a Neurol Rehabilitationszentrum G   (Germany)

^b UNIVERSITY OF COLOGNE   (Germany)

^c CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Botulinum toxin; Post traumatic headache; Traumatic brain injury

Indexed keywords

ANALGESIC AGENT; BOTULINUM TOXIN; BOTULINUM TOXIN A; NONSTEROID ANTIINFLAMMATORY AGENT; TRICYCLIC ANTIDEPRESSANT AGENT;

ADULT; ARTICLE; ATTENTION DEFICIT DISORDER; BRAIN DAMAGE; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; CONTUSION; FATIGUE; FEMALE; FOLLOW UP; HEAT TREATMENT; HEMATOMA; HEMIPARESIS; HUMAN; PAIN; PHYSIOTHERAPY; POSTTRAUMATIC HEADACHE; PSYCHOTHERAPY; STRESS;

EID: 84875127397     PISSN: 00283843     EISSN: 18974260     Source Type: Journal    
DOI: 10.5114/ninp.2012.32109     Document Type: Article

References (27)

1. Bouillon B., Raum M., Fach H., et al. The incidence and outcome of severe brain trauma - design and first results of an epidemiological study in an urban area. Restor Neurol Neurosci 1999; 14: 85-92.
2. Pfaffenrath V. Differenzialdiagnostische Tipps für die Praxis. So packen Sie den Kopfschmerz an der Wurzel. MMW Fortschr Med 2008; 150: 46-49.
3. Keidel M., Diener H.C. Der posttraumatische Kopfschmerz. Nervenarzt 1997; 68: 769-777.
4. Keidel M., Neu I., Langohr H.D., et al. Therapie des posttraumatischen Kopfschmerzes nach Schädel-Hirn-Trauma und HWS-Distorsion. Empfehlungen der Deutschen Migräne- und Kopfschmerzgesellschaft. Manuelle Medizin 2001; 39: 259.
5. Keidel M. Posttraumatischer Kopfschmerz. Nervenheilkunde 2007; 26: 156-158.
6. Wacker H.R. Epidemiologie und Komorbidität von Depressionen. Therapeutische Umschau. Rev Ther 2000; 57: 53-58.
7. Jost W.H. Botulinumtoxin beim Kopfschmerz vom Spannungstyp. Fortschr Neurol Psychiatr 2003; 71: 296-299.
8. Dowson A.J., Kilminster S.G., Salt R. Clinical profile of botulinum toxin A in patients with chronic headaches and cervical dystonia: a prospective, open-label, longitudinal study conducted in a naturalistic clinical practice setting. Drugs R D 2008; 9: 147-158.
9. Hamdy S.M., Samir H., El-Sayed M., et al. Botulinum toxin: could it be an effective treatment for chronic tension-type head - ache? J Headache Pain 2009; 10: 27-34.
10. Evers S. Review of botulinum toxin type A for the prophylactic treatment of chronic daily headache. Neuropsychiatr Dis Treat 2007; 3: 761-764.
11. Chan V.W., McCabe E.J., MacGregor D.L. Botox treatment for migraine and chronic daily headache in adolescents. Neurosci Nurs 2009; 41: 235-243.
12. Magalhães E., Menezes C., Cardeal M., et al. Botulinum toxin type A versus amitriptyline for the treatment of chronic daily migraine. Clin Neurol Neurosurg 2010; 112: 463-466.
13. Shuhendler A.J., Lee S., Siu M., et al. Efficacy of botulinum toxin type A for the prophylaxis of episodic migraine headaches: a meta-analysis of randomized, double-blind, placebo-controlled trials. Pharmacotherapy 2009; 29: 784-791.
14. De Ru J.A., Buwalda J. Botulinum toxin A injection into corrugator muscle for frontally localised chronic daily headache or chronic tension-type headache. J Laryngol Otol 2009; 123: 412-417.
15. Mathew N.T., Frishberg B.M., Gawel M., et al. Botulinum toxin type A (BOTOX®) for the prophylactic treatment of chronic daily headache: a randomized, double-blind, placebocontrolled trial. Headache 2005; 45: 293-307.
16. Freitag F.G., Diamond S., Diamond M., et al. Botulinum toxin type A in the treatment of chronic migraine without medication overuse. Headache 2008; 48: 201-209.
17. Silberstein S., Mathew N., Saper J., et al. The BOTOX®Mi - graine Clinical Research Group. Botulinum toxin type A as a mi - graine preventive treatment. Headache 2000; 40: 445-450.
18. Silberstein S.D., Stark S.R., Lucas S.M., et al. Botulinum toxin type A for the prophylactic treatment of chronic daily head - ache: a randomized, double-blind, placebo-controlled trial. Mayo Clin Proc 2005; 80: 1126-1137.
19. Aurora S.K., Gawel M., Brandes J.L., et al. Botulinum toxin type A prophylactic treatment of episodic migraine: a randomi - zed, double-blind, placebo-controlled exploratory study. Headache 2007; 47: 486-499.
20. Silberstein S.D., Gobel H., Jensen R. Botulinum toxin type A in the prophylactic treatment of chronic tension-type headache: a multicentre, double-blind, randomized, placebo-controlled, parallel-group study. Cephalalgia 2006; 26: 790-800.
21. Dodick D.W., Turkel C.C., Degryse R.E. Onabotulinumtoxin A for treatment of chronic migraine: pooled results from the double-blind, randomized placebo-controlled phases of the PREEMPT clinical program. Headache 2010; 50: 921-936.
22. Aurora S.K., Dodick D.W., Turkel C.C. Onabotulinumtoxin A for treatment of chronic migraine: results from the doubleblind, randomized placebo-controlled phase of the PREEMPT 1 trial. Cephalalgia 2010; 30: 793-803.
23. Diener H.C., Dodick D.W., Aurora S.K. Onabotulinumtoxin A for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial. Cephalalgia 2010; 30: 804-814.
24. Saper J.R., Mathew N.T., Loder E.W., et al. A double-blind, randomized, placebo-controlled comparison of botulinum toxin type a injection sites and doses in the prevention of episodic migraine. Pain Med 2007; 8: 478-485.
25. Elkind A.H., O'Carroll P., Blumenfeld A., et al. A series of three sequential, randomized, controlled studies of repeated treatments with botulinum toxin type A for migraine prophylaxis. J Pain 2006; 7: 688-696.
26. Relja M., Poole A.C., Schoenen J., et al. A multicentre, doubleblind, randomized, placebo-controlled, parallel group study of multiple treatments of botulinum toxin type A (BoNTA) for the prophylaxis of episodic migraine headaches. Cephalalgia 2007; 27: 492-503.
27. Mitchell M.P., Schaecher K., Cannon H.E., et al. Humanistic, utilization, and cost outcomes associated with the use of botulinum toxin for treatment of refractory migraine headaches in a managed care organization. J Manag Care Pharm 2008; 14: 442-450.